Cellix Biosciences Inc., a development-stage pharmaceutical company, today announced successful completion of a Pre-Investigational New Drug meeting with the U.S. Food and Drug Administration for the development of CLX-103, a novel molecular conjugate of mesalamine for the treatment of mild to moderate ulcerative colitis.
Ook interessant voor je
Reageer